Literature DB >> 12505256

Analysis of BRCA1, TP53, and TSG101 germline mutations in German breast and/or ovarian cancer families.

Vera Balz1, Hans Bernd Prisack, Henning Bier, Hans Bojar.   

Abstract

About 5%-10% of breast cancers are considered to be hereditary and associated with germline mutations of specific genes. As yet, the most frequently affected genes identified are BRCA1 and BRCA2, but also other genes such as TP53 are supposed to influence the predisposition toward breast cancer. In the present study, we analyzed patients of 19 German families with early onset breast cancer and/or a family history of breast and/or ovarian cancer for the presence of mutations in BRCA1 and TP53. In addition, we screened for germline mutations in the putative tumor suppressor gene TSG101. For this purpose we used direct sequence analysis of the entire coding regions for all three genes and, in the case of BRCA1, single-strand conformation polymorphism analysis and protein transcription-translation assays. We identified eight previously described polymorphisms and several aberrations in BRCA1: 1 unclassified missense mutation, 3 small protein truncating mutations, 1 novel pseudoexon, and 5 splicing variants. No mutation was detected in TP53. Analysis of TSG101 transcripts revealed an aberrant transcript in two breast cancer patients belonging to the same family, suggesting TSG101 as a predisposing gene in hereditary breast cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12505256     DOI: 10.1016/s0165-4608(02)00601-5

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  6 in total

Review 1.  Deep intronic mutations and human disease.

Authors:  Rita Vaz-Drago; Noélia Custódio; Maria Carmo-Fonseca
Journal:  Hum Genet       Date:  2017-05-12       Impact factor: 4.132

2.  High expression of tumor susceptibility gene 101 (TSG101) is associated with more aggressive behavior in colorectal carcinoma.

Authors:  Elmira Gheytanchi; Leili Saeednejad Zanjani; Roya Ghods; Maryam Abolhasani; Marzieh Shahin; Somayeh Vafaei; Marzieh Naseri; Fahimeh Fattahi; Zahra Madjd
Journal:  J Cancer Res Clin Oncol       Date:  2021-02-22       Impact factor: 4.553

Review 3.  Defective splicing, disease and therapy: searching for master checkpoints in exon definition.

Authors:  Emanuele Buratti; Marco Baralle; Francisco E Baralle
Journal:  Nucleic Acids Res       Date:  2006-07-19       Impact factor: 16.971

Review 4.  Role of pseudoexons and pseudointrons in human cancer.

Authors:  Maurizio Romano; Emanuele Buratti; Diana Baralle
Journal:  Int J Cell Biol       Date:  2013-09-24

5.  An epigenetic signature in peripheral blood predicts active ovarian cancer.

Authors:  Andrew E Teschendorff; Usha Menon; Aleksandra Gentry-Maharaj; Susan J Ramus; Simon A Gayther; Sophia Apostolidou; Allison Jones; Matthias Lechner; Stephan Beck; Ian J Jacobs; Martin Widschwendter
Journal:  PLoS One       Date:  2009-12-18       Impact factor: 3.240

6.  The R72P P53 mutation is associated with familial breast cancer in Jewish women.

Authors:  T Ohayon; R Gershoni-Baruch; M Z Papa; T Distelman Menachem; S Eisenberg Barzilai; E Friedman
Journal:  Br J Cancer       Date:  2005-03-28       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.